US 11,274,074 B2Granted

Pharmaceutical composition for ANO1 antagonist with anticancer activity

AssigneeIndustry-Academic Cooperation Foundation, Yonsei University

InventorsWan Namkung, Ik Yon Kim, Yohan Seo, Jin Hwang Kim

Life of this patent

Estimating the term…

Abstract

The present disclosure relates to a novel anticancer pharmaceutical composition. The present disclosure achieves an anticancer effect using a compound effective in inhibiting the expression of ANO1 (TMEM16A). In addition, the present disclosure provides an ANO1 (TMEM16A) antagonist using the compound inhibiting the expression of ANO1 (TMEM16A).

Claims3

Dependent claims

An anticancer pharmaceutical composition comprising a compound represented by [Chemical Formula 5]:

as an active ingredient.

Dependencies are inferred from the claim text.

Facts

Application: 16/574,701Filed 18 Sep 2019
Priority: KR 10-2018-011205619 Sep 2018
Published: US 2020/0087250 A119 Mar 2020
Granted: 15 Mar 2022
Term ends: Not estimatedThe source records don’t support an estimate.

Classification21 codes

C07C 251/80
To carbon atoms of an unsaturated carbon skeleton: the carbon skeleton containing rings
C07D 271/10
Not condensed with other rings: 1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles
A61K 9/0095
Galenical forms not covered by A61K9/02 - A61K9/7023: drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets…
A61K 9/20
Medicinal preparations characterised by special physical form: pills, tablets, discs, rods

Family

US 2020/0087250 A1Pre-grant publication · published 19 Mar 2020
US 11,274,074 B2This patent

From the US filing history. Foreign family members aren’t listed.

Timeline

Citations

Open elsewhere

patentgrep

Loading patent…

patentgrepSearch patents

Back to results